223 related articles for article (PubMed ID: 32388937)
1. [The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019].
Wen CY; Xie ZW; Li YP; Deng XL; Chen XT; Cao Y; Ou X; Lin WY; Li F; Cai WP; Li LH
Zhonghua Nei Ke Za Zhi; 2020 Aug; 59(8):605-609. PubMed ID: 32388937
[No Abstract] [Full Text] [Related]
2. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.
Li Y; Xie Z; Lin W; Cai W; Wen C; Guan Y; Mo X; Wang J; Wang Y; Peng P; Chen X; Hong W; Xiao G; Liu J; Zhang L; Hu F; Li F; Zhang F; Deng X; Li L
Med; 2020 Dec; 1(1):105-113.e4. PubMed ID: 32838353
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
Yu M; Wang DC; Li S; Lei YH; Wei J; Huang LY
J Med Virol; 2022 Apr; 94(4):1513-1522. PubMed ID: 34837230
[TBL] [Abstract][Full Text] [Related]
4. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
[TBL] [Abstract][Full Text] [Related]
5. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
Zhu Z; Lu Z; Xu T; Chen C; Yang G; Zha T; Lu J; Xue Y
J Infect; 2020 Jul; 81(1):e21-e23. PubMed ID: 32283143
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
Qu J; Li GH; Wang JJ; He GF; Huang JJ; Chen Y; Qu Q; Chen XY; Lu Q
Clin Exp Pharmacol Physiol; 2021 Feb; 48(2):203-210. PubMed ID: 33090501
[TBL] [Abstract][Full Text] [Related]
7. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
Lan X; Shao C; Zeng X; Wu Z; Xu Y
Int J Clin Pharmacol Ther; 2021 May; 59(5):378-385. PubMed ID: 33624583
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 2019.
Xia Q; Dai W; Xu K; Ni Q; Li Y; Liu J; Zhao H; Guo Y; Yu L; Yi P; Su J; Lang G; Tao J; Shi D; Wu W; Wu X; Xu Y; Xu M; Yu L; Wang X; Cai H; Fang Q; Zhou J; Qiu Y; Li L
J Med Virol; 2021 Jul; 93(7):4446-4453. PubMed ID: 33448426
[TBL] [Abstract][Full Text] [Related]
9. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
Huang YQ; Tang SQ; Xu XL; Zeng YM; He XQ; Li Y; Harypursat V; Lu YQ; Wan Y; Zhang L; Sun QZ; Sun NN; Wang GX; Yang ZP; Chen YK
Front Pharmacol; 2020; 11():1071. PubMed ID: 32765274
[TBL] [Abstract][Full Text] [Related]
10. Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2.
Liu J; Du C; Pu L; Xiang P; Xiong H; Xie W; Chen Z; Li A
BMC Infect Dis; 2021 Aug; 21(1):885. PubMed ID: 34461841
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.
Bhattacharyya A; Kumar S; Sarma P; Kaur H; Prajapat M; Shekhar N; Bansal S; Avti P; Hazarika M; Sharma S; Mahendru D; Prakash A; Medhi B
Indian J Pharmacol; 2020; 52(4):313-323. PubMed ID: 33078733
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats.
Hu Y; Zuo M; Wang X; Wang R; Li L; Lu X; Jiang S
J Zhejiang Univ Sci B; 2021 Jul; 22(7):599-602. PubMed ID: 34269012
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.
Wang Z; Chen X; Lu Y; Chen F; Zhang W
Biosci Trends; 2020 Mar; 14(1):64-68. PubMed ID: 32037389
[TBL] [Abstract][Full Text] [Related]
16. [Clinical efficacy and safety of different antiviral regimens in patients with coronavirus disease 2019].
Gao X; Ma C; Ma Y; Wang X; Wei J; Feng T; Zhao G; Xu L; Zhou W; Zheng X; Zhao Q; Cao X
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Dec; 32(12):1423-1427. PubMed ID: 33541491
[TBL] [Abstract][Full Text] [Related]
17. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series.
Lepage MA; Rozza N; Kremer R; Grunbaum A
Clin Toxicol (Phila); 2021 Jul; 59(7):644-647. PubMed ID: 33641562
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.
Amani B; Amani B; Zareei S; Zareei M
Immun Inflamm Dis; 2021 Dec; 9(4):1197-1208. PubMed ID: 34347937
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.
Ye XT; Luo YL; Xia SC; Sun QF; Ding JG; Zhou Y; Chen W; Wang XF; Zhang WW; Du WJ; Ruan ZW; Hong L
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3390-3396. PubMed ID: 32271456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
